贝利尤单抗对原发性膜性肾病蛋白尿及抗PLA2R抗体的影响
这项前瞻性开放标签实验医学研究纳入14例持续性肾病范围蛋白尿的原发性膜性肾病患者,接受贝利尤单抗单药治疗(10 mg/kg每4周)最长2年。结果显示PLA2R-Ab从第12周起显著下降,蛋白尿从第36周起显著下降,9例达部分或完全缓解,不良事件与预期一致。
要点
- 贝利尤单抗单药可显著降低PMN患者PLA2R-Ab,第12周起差异有统计学意义。
- 蛋白尿从第36周起显著下降,9例中8例部分缓解、1例完全缓解。
- 基线白蛋白/胆固醇异常者在末次随访时恢复至正常或接近正常。
核心结论
- 贝利尤单抗治疗PMN可降低PLA2R-Ab并继而减少蛋白尿,是诱导缓解的重要前奏。
研究设计与样本
- 前瞻性、开放标签、实验医学研究,纳入14例原发性膜性肾病伴持续性肾病范围蛋白尿的受试者。
- 受试者接受贝利尤单抗单药治疗(10 mg/kg,每4周一次)最长2年,治疗后随访至6个月。
主要发现
- 意向治疗人群中,基线蛋白尿724 mg/mmol(95%CI 579-906)降至第28周498 mg/mmol(95%CI 383-649)和第104周130 mg/mmol(95%CI 54-312),自第36周起变化有统计学意义(n=11,P=0.047)。
- PLA2R-Ab从基线174 RU/mL(95%CI 79-384)降至第28周46 RU/mL(95%CI 16-132)和第104周4 RU/mL(95%CI 2-6),自第12周起有统计学意义(n=13,P=0.02)。
- 9例受试者达到缓解,其中部分缓解8例、完全缓解1例。
- 基线白蛋白和/或胆固醇异常者在末次随访时恢复至正常或接近正常水平。
- 不良事件与该人群预期一致。
临床怎么用
- 对于持续性肾病范围蛋白尿的PMN患者,贝利尤单抗单药可考虑作为降低PLA2R-Ab和蛋白尿的治疗选择。
- 治疗过程中应监测PLA2R-Ab和蛋白尿变化,PLA2R-Ab自第12周起、蛋白尿自第36周起可能出现显著改善。
局限性
- 研究为开放标签、单臂设计,样本量较小(14例),未设对照组。
- 仅11例完成至主要终点(第28周),9例完成整个研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immunosuppressant drugs reduce proteinuria and anti-phospholipase A2 receptor autoantibodies (PLA2R-Ab) in primary membranous nephropathy (PMN) with varying success and associated toxicities. This study aimed to evaluate the effect of belimumab on proteinuria and PLA2R-Ab in participants with PMN. METHODS: In this prospective, open-label, experimental medicine study, 14 participants with PMN and persistent nephrotic-range proteinuria received up to 2 years belimumab monotherapy (10 mg/kg, every 4 weeks). Changes in proteinuria (urinary protein:creatinine ratio), PLA2R-Ab, albumin, cholesterol, B-cell subsets and pharmacokinetics were analysed during treatment and up to 6 months after treatment. RESULTS: Eleven participants completed to the primary endpoint (Week 28) and nine participants completed the study. In the intention-to-treat population population, baseline proteinuria of 724 mg/mmol [95% confidence interval (CI) 579-906] decreased to 498 mg/mmol (95% CI 383-649) and 130 mg/mmol (95% CI 54-312) at Weeks 28 and 104, respectively, with changes statistically significant from Week 36 (n = 11, P = 0.047). PLA2R-Ab decreased from 174 RU/mL (95% CI 79-384) at baseline to 46 RU/mL (95% CI 16-132) and 4 RU/mL (95% CI 2-6) at Weeks 28 and 104, respectively, becoming statistically significant by Week 12 (n = 13, P = 0.02). Nine participants achieved partial (n = 8) or complete (n = 1) remission. Participants with abnormal albumin and/or cholesterol at baseline gained normal/near normal levels by the last follow-up. Adverse events were consistent with those expected in this population. CONCLUSIONS: Belimumab treatment in participants with PMN can reduce PLA2R-Ab and subsequently proteinuria, important preludes to remission induction.
引用
- Barrett C, Willcocks LC, Jones RB, et al. Effect of belimumab on proteinuria and anti-phospholipase A2 receptor autoantibody in primary membranous nephropathy. Nephrol Dial Transplant. 2020. PMID: 31243451. doi:10.1093/ndt/gfz086
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。